Please check your internet connection and try again.
# Tranexamic Acid
## Overview
Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. It is available as oral tablets and intravenous (IV) solution.
## Primary Indications
* **Hemorrhage:** Management of severe traumatic hemorrhage (CRASH-2 protocol) and postpartum hemorrhage.
* **Surgical Hemostasis:** Prevention of blood loss in major orthopedic, cardiac, and spinal surgeries.
* **Menorrhagia:** Treatment of cyclic heavy menstrual bleeding.
* **Hereditary Angioedema:** Short-term prophylaxis for dental or minor surgical procedures.
## Adult Dosing
* **Trauma/Acute Hemorrhage:** 1 g IV bolus over 10 minutes, followed by 1 g infusion over 8 hours. Administer within 3 hours of injury.
* **Menorrhagia:** 1,300 mg orally three times daily for up to 5 days during menstruation.
* **Surgical Prophylaxis:** Dosing varies widely by protocol (e.g., 10–30 mg/kg IV bolus, sometimes followed by infusion). Consult institutional surgical guidelines.
## Pediatric Dosing
* **Trauma/Hemorrhage:** 10–20 mg/kg IV bolus (max 1 g), followed by 2–10 mg/kg/hr infusion.
* **Hereditary Angioedema:** 25 mg/kg orally up to 3 times daily (max 1.5 g per dose).
* *Note: Pediatric dosing is often institution-specific; verify weight-based protocols before administration.*
## Dose Adjustments
* **Renal Impairment:** Requires dose reduction in patients with CrCl <50 mL/min.
* CrCl 30–50 mL/min: 50% of standard dose.
* CrCl 10–30 mL/min: 25% of standard dose.
* CrCl <10 mL/min: 10% of standard dose.
* **Hepatic Impairment:** No specific data; dose adjustments are generally not required due to minimal hepatic metabolism.
## Contraindications
* Active intravascular clotting (thromboembolic disease).
* History of deep vein thrombosis (DVT) or pulmonary embolism (PE).
* Subarachnoid hemorrhage (due to risk of cerebral ischemia).
* Acquired defective color vision (prevents clinical monitoring).
* Hypersensitivity to TXA.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain (especially with oral formulations).
* **Serious:** Thromboembolic events (DVT, PE, MI, stroke), seizures (particularly with rapid IV injection or high-dose cardiac surgery), and visual disturbances.
## Key Drug Interactions
* **Thrombolytics:** Concomitant use with fibrinolytic agents (e.g., tPA) antagonizes the effect of the thrombolytic.
* **Estrogens/Oral Contraceptives:** May increase the risk of thrombosis if used concurrently due to the prothrombotic nature of estrogens.
* **Prothrombin Complex Concentrates (PCCs)/Factor IX:** Increased risk of thrombotic complications.
## Monitoring
* **Coagulation status:** Monitor for signs of persistent bleeding or venous thromboembolism (VTE).
* **Neurological:** Monitor for seizure activity, especially in patients with a history of epilepsy or high-dose rapid infusion.
* **Renal:** Monitor serum creatinine in patients with impaired function.
## Clinical Pearls
* **Rapid Administration:** Avoid rapid IV bolus injections; these can cause hypotension and increase the risk of seizures. Always infuse over at least 10 minutes.
* **Storage:** IV solution is compatible with most standard IV fluids.
* **Standardization:** Always follow location-specific massive transfusion protocols (MTP), as dosing for perioperative and traumatic hemorrhage varies significantly between institutions.
* **Topical Use:** TXA is increasingly used topically in orthopedic surgery (e.g., intra-articular) to reduce blood loss with minimal systemic absorption.
***
*Disclaimer: This information is for educational purposes only. Always consult current pharmacological resources, institutional clinical guidelines, and the manufacturer’s package insert to verify dosages and safety information before prescribing or administering medication.*
